Janus Henderson Group plc 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 11:34 am Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
JANUS HENDERSON GROUP PLC JHG |
2,252,240 4.900% |
-884,847 (-28.21%) |
Filing |
| 2024-11-14 3:15 pm Purchase |
2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
JANUS HENDERSON GROUP PLC JHG |
3,137,087 6.000% |
43,791 (+1.42%) |
Filing |
| 2024-02-13 10:56 am Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
JANUS HENDERSON GROUP PLC JHG |
3,093,296 7.200% |
1,627,029 (+110.96%) |
Filing |
| 2023-02-09 09:07 am Sale |
2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
JANUS HENDERSON GROUP PLC JHG |
1,466,267 4.500% |
-181,656 (-11.02%) |
Filing |
| 2022-02-11 3:19 pm Purchase |
2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
JANUS HENDERSON GROUP PLC JHG |
1,647,923 5.100% |
1,647,923 (New Position) |
Filing |